Evaluation Of Anemia After Long-Term Treatment With Imatinib In Chronic Myeloid Leukemia In Chronic Phase

被引：0
|
作者：
Moura, Muriel Silva
Pagnano, Katia B.
Benevides, Thais
De Souza, Carmino A., Sr.
Lorand-Metze, Irene
Delamain, Marcia T.
Duarte, Gislaine O.
Pericole, Fernando V.
Percout, Priscila
Dias, Maria
Duarte, Bruno
Campos, Paula
Assuncao, Paola
Oliveira, Luciene
Paul, Pamela
Fernandes, Eliana
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.5200.5200
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5200
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib
    Schmid, Hansjoerg
    Jaeger, Bernadette A. S.
    Lohse, Judith
    Suttorp, Meinolf
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (08): : 1177 - 1179
  • [22] Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
    Shah, Neil P.
    Guilhot, Francois
    Cortes, Jorge E.
    Schiffer, Charles A.
    le Coutre, Philipp
    Bruemmendorf, Tim H.
    Kantarjian, Hagop M.
    Hochhaus, Andreas
    Rousselot, Philippe
    Mohamed, Hesham
    Healey, Diane
    Cunningham, Michael
    Saglio, Giuseppe
    BLOOD, 2014, 123 (15) : 2317 - 2324
  • [23] Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Stagno, F.
    Iurlo, A.
    Albano, F.
    Abruzzese, E.
    Martino, B.
    Levato, L.
    Intermesoli, T.
    Pregno, P.
    Rossi, G.
    Gherlinzoni, F.
    Leoni, P.
    Cavazzini, F.
    Venturi, C.
    Soverini, S.
    Testoni, N.
    Alimena, G.
    Cavo, M.
    Martinelli, G.
    Pane, F.
    Saglio, G.
    Rosti, G.
    Baccarani, M.
    LEUKEMIA, 2015, 29 (09) : 1823 - 1831
  • [24] Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
    F Castagnetti
    G Gugliotta
    M Breccia
    F Stagno
    A Iurlo
    F Albano
    E Abruzzese
    B Martino
    L Levato
    T Intermesoli
    P Pregno
    G Rossi
    F Gherlinzoni
    P Leoni
    F Cavazzini
    C Venturi
    S Soverini
    N Testoni
    G Alimena
    M Cavo
    G Martinelli
    F Pane
    G Saglio
    G Rosti
    M Baccarani
    Leukemia, 2015, 29 : 1823 - 1831
  • [25] Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
    Cheng, Fang
    Yuan, Guolin
    Li, Qiang
    Cui, Zheng
    Li, Weiming
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [26] Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure
    Gusarova, Galina
    Bykova, Anastasia
    Vorontsova, Alexandra
    Kuznetsov, Sergey
    Shukhov, Oleg
    Chelysheva, Ekaterina
    Lazareva, Olga
    Goryacheva, Svetlana
    Ivanova, Tatyana
    Turkina, Anna G.
    BLOOD, 2015, 126 (23)
  • [27] Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy
    Tantiworawit, Adisak
    Power, Maryse M.
    Barnett, Michael J.
    Hogge, Donna E.
    Nantel, Stephen H.
    Nevill, Thomas J.
    Shepherd, John D.
    Song, Kevin W.
    Sutherland, Heather J.
    Toze, Cynthia L.
    Abou-Mourad, Yasser R.
    Narayanan, Sujaatha
    Broady, Raewyn C.
    Forrest, Donna L.
    LEUKEMIA & LYMPHOMA, 2012, 53 (07) : 1321 - 1326
  • [28] Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study
    Savas, Emine Merve
    Yilmaz, Seda
    Dikyar, Ayse Asena Baser
    Ozkurt, Zubeyde Nur
    Ocal, Ramazan
    Can, Ferda
    Pepeler, Sezgin
    Kaynar, Lale Aydin
    Gokcen, Sanem
    Yildiz, Abdulkerim
    Albayrak, Murat
    Karakus, Sema
    Ceneli, Ozcan
    Yagci, Munci
    TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 (04) : 236 - 241
  • [29] Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia.
    Kim, Dong Hwan
    Kim, Jung A.
    Yun, Jina
    Sriharsha, Lakshrmi
    Jang, Jun Ho
    Kim, Kihyun
    Jung, Chul Won
    Kamel-Reid, Suzanne
    Radich, Jerald
    Lipton, Jeffrey H.
    BLOOD, 2009, 114 (22) : 455 - 455
  • [30] Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure.
    Lipton, Jeffrey Howard
    Cortes, Jorge E.
    Khoury, Hanna Jean
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Zeremski, Mirjana
    Bardy-Bouxin, Nathalie
    Shapiro, Mark
    Leip, Eric
    Gambacorti-Passerini, Carlo
    Bruemmendorf, Tim H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345